Clarivate Plc

Clarivate Plc (CLVT) Market Cap

Clarivate Plc has a market capitalization of $1.27B.

Price: $1.98

-0.03 (-1.49%)

Market Cap: 1.27B

NYSE · time unavailable

CEO: Matitiahu Shem Tov

Sector: Technology

Industry: Information Technology Services

IPO Date: 2018-10-29

Website: https://www.clarivate.com

Clarivate Plc (CLVT) - Company Information

Market Cap: 1.27B|Sector: Technology

Company Profile

Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.

Analyst Sentiment

52%
Hold

From 9 Active Polls

1Y Forecast: $2.00

▲ +1.0% Potential Upside

Consensus Target Metrics

Low Bound

$2

Median

$2

High Bound

$2

Average

$2

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$2.00
▲ +1.01% Upside
Low Target
$2.00
1% Risk
Median Target
$2.00
1% Mid
High Target
$2.00
1% Max
Consensus
Hold
6 / 21 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)1,2671,3811,6212,1852,5602,9302,7113,5705,103
Enterprise Value ($M)5,3065,4215,7236,3356,7217,1546,9527,8689,427
Price to Earnings Ratio (P/E)-3.81-1.29-10.09177.66-22.64-9.77-6.55-4.70-19.44
Price/Earnings-to-Growth Ratio (PEG)-4.18-82.74-2.09-0.72
Price to Sales Ratio (P/S)0.522.352.773.544.114.714.575.388.20
Price to Book Ratio (P/B)0.280.300.340.450.520.590.540.690.93
Price to Free Cash Flow Ratio (P/FCF)2.1738.4720.546.2022.1658.2424.5860.4140.40
Enterprise Value to Sales (EV/Sales)9.239.7710.2710.7911.5111.7111.8715.15
Enterprise Value to EBITDA (EV/EBITDA)11.05-27.0826.7927.4828.4228.8632.1463.6047.39
Debt to Equity Ratio8.410.940.910.920.910.920.910.890.85

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CLARIVATE PLC (CLVT) — Investment Overview

🧩 Business Model Overview

Clarivate provides research and intellectual-property (“IP”) intelligence through subscription databases and workflow tools. In research workflows, Clarivate’s products support scholarly discovery, citation analytics, grant and portfolio decisions, and research evaluation. In IP workflows, Clarivate products support patent search, patent landscape analytics, and competitive monitoring across prosecution strategy and enforcement planning. The value proposition centers on curated, structured data and analytics embedded into recurring decision processes for universities, government bodies, and corporate R&D/IP organizations.

💰 Revenue Streams & Monetisation Model

The revenue model is primarily subscription-led: institutional and enterprise customers pay for access to databases, analytics platforms, and related software-enabled services. Monetisation typically reflects:

  • Recurring subscriptions tied to usage and seat/device structures, supporting high renewal visibility.
  • Tiered analytics and workflow add-ons that expand within the same account over time as customers adopt more modules (e.g., deeper citation analytics, research performance measurement, or IP landscape capabilities).
  • Professional and service components that supplement subscriptions (implementation, training, and specialized analytics), usually with a smaller contribution than recurring access fees.

Margin structure generally benefits from a software/data cost base: once content, taxonomy, and platform infrastructure are built and maintained, incremental revenue tends to scale with less proportional cost, while customer retention and expansion drive operating leverage.

🧠 Competitive Advantages & Market Positioning

Clarivate’s core moat is a combination of high switching costs and intangible assets (proprietary data curation, classification systems, and analytic frameworks).

  • Switching Costs (Workflow + Data Gravity): Customers integrate Clarivate outputs into internal reporting, research evaluation, and IP strategy processes. Historical baselines, standardized fields, and user training create inertia, making replacement across platforms costly and operationally disruptive.
  • Intangible Assets (Curated Data + Analytics): Maintaining reliable coverage, cleaning, normalization, and evolving classification logic is difficult. Competitors can assemble data from sources, but replicating Clarivate’s structured, validated, and analytics-ready datasets is a sustained investment effort.
  • Embedded Enterprise Relationships: Institutional procurement cycles and multi-year licensing arrangements reinforce retention, particularly where evaluation frameworks and compliance requirements rely on consistent data methodologies.

Competitive benchmarking:

  • Elsevier (RELX) — strong in scholarly indexing and research analytics, with a broad footprint in academic publishing. Clarivate’s emphasis spans both scholarly intelligence and IP analytics within a unified enterprise workflow for discovery and competitive positioning.
  • Springer Nature / Dimensions — a research analytics alternative. Clarivate differentiates through the depth of curated data workflows and a comparatively larger focus on linking research evaluation needs with IP-oriented intelligence.
  • Questel (and peers such as CPA Global) — focused heavily on IP/patent intelligence. Clarivate’s competitive positioning leverages cross-domain datasets and analytics to serve both corporate R&D decision-making and IP strategy, where buyers often seek an integrated intelligence layer rather than point solutions.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, Clarivate’s addressable market expands through structural demand for data-driven decision support in R&D and IP.

  • Increasing R&D complexity and volume: More publications, more collaborations, and more multidisciplinary work elevate the value of robust discovery, normalization, and evaluation analytics.
  • Growing importance of patent landscape and competitive intelligence: Higher global IP activity increases demand for faster, more accurate searching and landscape modeling.
  • Institutional accountability and research evaluation: Governments, universities, and research funders increasingly require auditable, consistent metrics for portfolio decisions—benefiting providers with stable methodologies.
  • Workflow digitization and integration: Customers adopt tools that embed intelligence into end-to-end processes (search → evaluation → strategy), supporting upsell opportunities from foundational access into advanced analytics modules.
  • AI-assisted research and IP analysis: AI does not remove the need for curated, structured inputs. Organizations still require authoritative datasets, normalization, and consistent taxonomies to use AI outputs responsibly—supporting ongoing demand for high-quality data infrastructure.

⚠ Risk Factors to Monitor

  • Pricing pressure and competitive displacement: Public and private competitors may discount or bundle content/services, challenging renewal rates and expansion economics.
  • Data integrity and platform performance: Any degradation in data quality, classification accuracy, coverage, or analytics reliability can increase churn and reduce customer trust.
  • Technological disruption in scholarly and IP discovery: New search paradigms or data access models could reduce perceived differentiation if customers believe they can substitute analytics with alternative tools.
  • Customer concentration and budget cyclicality: Public-sector and academic budgets can influence renewal timing and module adoption.
  • Acquisition integration risk: Product portfolio integration, retention of key customers, and realization of synergy targets can affect the medium-term margin profile.
  • Regulatory and privacy/sublicensing constraints: Licensing terms for content and compliance requirements tied to data handling can impact operating flexibility.

📊 Valuation & Market View

The market typically values data/software and subscription information providers using a mix of EV/EBITDA and P/S, with equity sensitivity to subscription quality. Valuation tends to move with:

  • Recurring revenue durability (renewal rates, churn control).
  • Operating margin stability and operating leverage (software/data cost discipline and disciplined spending).
  • Expansion within installed accounts (module adoption and usage-driven upsells).
  • Free cash flow conversion (maintenance of predictable working capital needs and capex intensity).

Given the subscription-led profile and retention-driven economics, investors generally reward businesses that demonstrate consistent renewal strength and incremental monetisation across their customer base.

🔍 Investment Takeaway

Clarivate’s long-term thesis rests on structural switching costs and durable intangible assets in curated research and IP intelligence. The company competes in a market with credible, well-funded rivals, yet Clarivate’s embedded workflows and proprietary data/analytics frameworks make replacement operationally difficult for institutional and enterprise customers. Upside appears tied to sustained subscription renewals and continued account expansion as R&D and patent strategy demand grows, while key risks center on competitive pricing pressure and maintaining data/analytics reliability.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CLVT.

defenseworld.net2026-07-31

First Trust Advisors LP Has $13.97 Million Stock Holdings in Clarivate PLC $CLVT

First Trust Advisors LP lifted its stake in shares of Clarivate PLC (NYSE: CLVT) by 10.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,522,601 shares of the company's stock after acquiring an additional 516,418 shares during the quarter.

marketbeat.com2026-07-29

Clarivate Q2 Earnings Call Highlights

Clarivate NYSE: CLVT said during its earnings call that it expects organic recurring revenue and annualized contract value growth to improve in the second half of the year, citing renewal visibility, product momentum and a growing pipeline of AI-enabled offerings.

seekingalpha.com2026-07-29

Clarivate Plc (CLVT) Q2 2026 Earnings Call Transcript

Clarivate Plc (CLVT) Q2 2026 Earnings Call Transcript

zacks.com2026-07-29

Clarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com2026-07-29

Clarivate PLC (CLVT) Q2 Earnings and Revenues Beat Estimates

Clarivate PLC (CLVT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.18 per share a year ago.

prnewswire.com2026-07-29

Clarivate Appoints Michael Easton as Chief Financial Officer

Experienced Clarivate leader brings more than 25 years of financial and operational expertise LONDON, July 29, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative intelligence, today announced the appointment of Michael Easton as Executive Vice President and Chief Financial Officer, effective August 8, 2026. He succeeds Jonathan Collins who is stepping down as CFO to pursue another opportunity.

prnewswire.com2026-07-29

Clarivate Reports Second Quarter 2026 Results

— Delivers continued progress on strategic and financial priorities through Value Creation Plan —— Sharpens focus and enhances financial profile with previously announced Life Sciences & Healthcare segment divestiture —— Reaffirms 2026 financial outlook — LONDON, July 29, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2026. Executive Commentary Matti Shem Tov, Chief Executive Officer: "The Value Creation Plan continues to drive meaningful progress, as we execute against our strategic priorities and strengthen Clarivate's foundation for organic growth acceleration.

prnewswire.com2026-07-20

Clarivate RiskMark Wins 2026 CODiE Award for Best AI Tool for Lawyers

Prestigious awards program recognizes innovative AI technology transforming trademark risk assessment for legal professionals LONDON, July 20, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that RiskMark has been named the winner of the 2026 CODiE Award for Best AI Tool for Lawyers. The award recognizes AI-driven solutions that significantly enhance the efficiency, accuracy and capabilities of legal professionals through advanced technology.

prnewswire.com2026-07-16

USPTO Launches AI Image Search in Trademark Search System, Powered by Clarivate

LONDON, July 16, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, is proud to support the U.S. Patent and Trademark Office (USPTO) in launching an AI assisted image search within its public trademark search system, TM Search. This new capability allows users to upload and compare images against the U.S. trademark register and has been selected and awarded a contract by the USPTO.

prnewswire.com2026-07-14

Clarivate Selected by Abes to Modernize French National Academic Library System

New cloud-based, shared and scalable platform based on Alma, Primo and Rapido creates a unified library experience Library services, resource sharing and AI-powered discovery in one platform LONDON, July 14, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today that the Bibliographic Agency for Higher Education (Abes) has selected the company to modernize France's national academic library system, under a multi-year agreement. Abes supports higher education and research institutions across France with a documentation system including shared library data and services.

marketbeat.com2026-07-12

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate NYSE: CLVT said it has reached an agreement to sell substantially all of its Life Sciences & Healthcare segment to Altaris, an investment firm focused on the healthcare industry, in a transaction valued at $600 million.

prnewswire.com2026-07-10

Clarivate to Report Second Quarter 2026 Results on July 29, 2026

LONDON, July 10, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the second quarter 2026 before the market opens on Wednesday, July 29, 2026. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.

seekingalpha.com2026-07-06

Clarivate Plc (CLVT) M&A Call Transcript

Clarivate Plc (CLVT) M&A Call Transcript

prnewswire.com2026-07-06

Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company's focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and lowering capital intensity; proceeds to be used to reduce debt Reaffirms full-year 2026 financial outlook Conference call and webcast scheduled for 9:00 AM eastern time LONDON, July 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative intelligence, today announced it has entered into a definitive agreement to divest its Life Sciences & Healthcare ("LS&H") segment to Altaris LLC, an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, for $600 million. Following the close of the transaction, Clarivate will be a subscription-first global provider of intelligence solutions, workflow software and tech-enabled services for its leading Academia & Government ("A&G") and Intellectual Property ("IP") segments.

prnewswire.com2026-06-23

Clarivate Releases 2025 Sustainability Report

New report highlights progress against goals and a decline in total carbon emissions LONDON, June 23, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released its 2025 Sustainability Report, highlighting continued progress against its sustainability goals, including reduction of total reported greenhouse gas emissions by 24%. Clarivate partners with 45,000 organizations worldwide, including universities, research institutions, corporations, law firms, government agencies and life science and healthcare companies to address global challenges.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"CLVT reported Q2’26 revenue of $587.3M and net income of -$268.6M (EPS -$0.42). On a YoY basis, revenue was down -5.4% (Q2’26 vs Q2’25), while net income deterioration was material (from -$72.0M to -$268.6M; ~-273% YoY). QoQ, revenue was essentially flat (+0.3%), but losses widened sharply as net income fell from -$40.2M in Q1’26 to -$268.6M in Q2’26. Profitability is contracting: gross margin remains very high (~68.4% in Q2’26) but operating and net margins are deeply negative (operating margin -34.1%, net margin -45.7%). Cash flow improved versus the income statement: operating cash flow (OCF) was +$90.6M, producing positive free cash flow of +$35.9M, aided by non-cash items and working-capital effects. Capital expenditure was modest (-$54.7M), and the company used a small amount of cash for financing (no dividends; $18.1M buybacks; net financing outflow of -$50.8M). Balance sheet resilience is mixed: total assets were $10.49B with equity of $4.54B, but leverage remains elevated with net debt of $4.04B. Total shareholder return looks weak: the stock is down -22.99% over 1Y and offers a 0% dividend yield. With consensus target at $2.50 versus a $2.68 price, upside is limited."

Revenue Growth

Caution

Revenue was -5.4% YoY in Q2’26 ($587.3M vs $621.4M) and nearly flat QoQ (+0.3% vs $585.5M). Trend is slightly down on an annual basis.

Profitability

Neutral

Despite strong gross margin (~68.4%), operating margin contracted to -34.1% in Q2’26 (from +5.2% in Q1’26) and net income losses widened to -$268.6M (from -$40.2M QoQ). YoY net income deteriorated ~-273%.

Cash Flow Quality

Fair

OCF remained positive at +$90.6M and free cash flow was +$35.9M in Q2’26, even with net losses. However, the quality versus earnings is mixed given the large gap between net income and OCF.

Leverage & Balance Sheet

Caution

Equity is sizable ($4.54B) and relatively stable QoQ (from $4.79B), but leverage remains high with net debt of $4.04B and total assets of $10.49B. Losses also weigh on retained earnings (still deeply negative).

Shareholder Returns

Neutral

Stock price momentum is weak (-22.99% 1Y) and dividend yield is 0%. Buybacks were modest ($18.1M in Q2’26), so total shareholder return is pressured.

Analyst Sentiment & Valuation

Fair

Consensus target is $2.50 vs current ~$2.68, implying slightly negative near-term upside. Not a strong valuation tailwind based on the provided target.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Clarivate’s Q2 largely confirms the company’s transition playbook: organic ACV grew 1.5% YoY and management highlighted expanding profit margin (>42%) alongside disciplined cost control, while recurring mix continues shifting toward subscription. However, the quarter’s GAAP loss ($269M) was dominated by a non-cash impairment tied to the agreed LS&H divestiture to Altaris, which management expects to close by year-end. Full-year guidance was refined for discontinued-ops treatment of LS&H: A&G is guided to approach 3% growth, IP to return to growth by year-end, and blended organic growth to ~2.25%, with recurring organic growth ~1.5% near the midpoint and adjusted EBITDA margin expanding ~200 bps. Capital allocation remains active—another $75M bond repurchase—and the company targets ~$900M debt reduction using H2 free cash flow plus divestiture proceeds. Key debate in Q&A centered on renewal timing normalcy, MCP monetization, and whether transactional weakness in LS&H reflected specific customer issues (management: no discrete client).

AI IconGrowth Catalysts

  • Web of Science Research Intelligence launched globally (AI-native platform for research strategy/impact/funding); generated a multimillion-dollar ACV pipeline and secured 77 paying customers to date
  • Nexus Connect (AI-native single university connector integrating AI chat agents like ChatGPT and Claude) aimed at embedding Clarivate intelligence into academic research workflows
  • IP-1 (unified agentic AI platform for patent and trademark intelligence plus IP workflow across the lifecycle); development with corporate IP teams and law firms
  • RiskMark recognized as best AI tool for lawyers (2026 CODiE); second recognition since 2025 LegalTech Predictive AI Solution of the Year
  • Recurring mix shift via subscription-first model; pro forma recurring revenue mix expected to rise from 89% to ~92% after LS&H sale

Business Development

  • Web of Science Research Intelligence: 50+ development partners/early adopters across 20 countries
  • Nexus Connect: positioned to integrate with AI chat platforms (explicitly named ChatGPT and Claude)
  • MCP opportunity: customers seek to embed Clarivate capabilities via Model Context Protocol into corporate AI infrastructure; embedded in/adjacent to generic LLM environments (explicitly referenced Anthropic and ChatGPT)
  • Life Sciences & Healthcare divestiture agreement with Altaris (announced early July); expected to close by end of 2026

AI IconFinancial Highlights

  • Q2 revenue: $587M; first-half revenue: nearly $1.2B
  • Q2 net loss: $269M driven by non-cash impairment charge tied to definitive agreement to divest LS&H
  • Adjusted diluted EPS: $0.19 in Q2 (up $0.01 YoY); first-half adjusted diluted EPS: $0.38 (19% increase YoY)
  • Organic ACV growth improved to 1.5% YoY; Academia & Government and Life Sciences & Healthcare each delivered 2% organic ACV growth
  • Profit margin expanded to >42% in Q2; full-year guidance: adjusted EBITDA margin expansion of ~200 bps
  • Full-year guidance refinement: organic annual contract value expected in lower half of range because LS&H excluded in second half (discontinued ops assumption for modeling)
  • Segment guidance: A&G approaches 3% organic growth; IP returns to growth by year-end; blended company organic growth ~2.25%
  • Recurring organic growth expected ~1.5% near midpoint of range (about +nearly 100 bps vs prior year); recurring organic revenue mix expected ~92% (above original high end) post-LS&H move
  • Full-year revenue expected just below midpoint at ~$2.35B, attributed entirely to foreign exchange impact
  • Free cash flow: now likely low end of range due to LS&H divestiture transaction costs (including nearly $70M one-time cost) and additional restructuring costs for incremental savings next year
  • Cash taxes expected $5M–$10M higher due largely to new corporate tax in Jersey; cash interest expected to improve by ~$20M YoY

AI IconCapital Funding

  • Repurchased $75M of bonds due in 2028 at ~3% discount
  • First-half debt reduction: $218M
  • Full-year target: reduce debt by about $900M using free cash flow (H2) plus LS&H divestiture proceeds
  • Expectation: free cash flow flat YoY in full year due to divestiture closing transaction costs; one-time cost nearly $70M does not recur next year

AI IconStrategy & Ops

  • Portfolio rationalization: announced agreement to sell LS&H segment to Altaris (VCP in action); move to discontinued operations simplifies operating model and subscription-first focus
  • Business model optimization: meaningful shift toward recurring subscription-based revenue to improve visibility/predictability/retention
  • Operational discipline: maintained adjusted EBITDA margin despite organic revenue decline; profit-margins expanding trend expected to continue through 2H
  • Capital spending: disposals and cost efficiencies expected to improve capital spending by ~$20M
  • Product/innovation roadmap execution: introduced agentic AI products Nexus Connect and IP-1; advanced AI enablement across existing offerings

AI IconMarket Outlook

  • Q2 guidance posture reiterated: results in line with original expectations; expect ACV and organic recurring revenue inflect in second half
  • As of end of July, A&G has ~75% of this year’s business in the bag; fall is a key renewal cycle, but management expects strong 2H visibility
  • Full-year (assume LS&H closure at year-end for modeling): adjusted EBITDA just over $1B with profit margin nearly 43% at midpoint; adjusted diluted EPS grows about 9% to $0.75 at midpoint
  • Recurring organic growth: ~1.5% near midpoint; company revenue now expected ~$2.35B just below midpoint
  • Foreign exchange: expected essentially flat YoY

AI IconRisks & Headwinds

  • Transactional revenue headwinds in LS&H during Q2; transactional declines partly reflect continued migration of transactional components into subscriptions plus remaining transactional exposure
  • Renewal timing can be lumpy quarter to quarter (management cited timing of renewals/possible quarter-specific lapping)
  • Non-cash impairment in Q2 tied to LS&H divestiture agreement can distort GAAP losses (net loss $269M)
  • Working capital: higher working capital use expected in 2H/for full year (use ~ $25M primarily due to incentive compensation payments); timing of collections/payments drove lower Q2 FCF YoY
  • Foreign exchange volatility is monitored; guidance assumes essentially flat FX for full year

Q&A: Analyst Interest

  • Renewals timing vs longer sales cycles: Management said Q2/1H match original expectations and that renewal timing is normal/lumpy quarter to quarter rather than an elongation. They cited end-June organic ACV of ~1.5% aligning with subscription revenue conversion and reaffirmed a 2H inflection with good line-of-sight.
  • MCP monetization mechanics and target users: Management framed MCP as an embedding path for bigger customers that want Clarivate proprietary intelligence inside their corporate AI products. They said early days, with revenue potential via new products/AI enablement and possibility of AI-specific pricing for new offerings rather than a confirmed single pricing model.
  • Transactional revenue decline attribution and Life Sciences deal process: Analysts asked whether any discrete client hurt Life Sciences transactions and whether deal terms (e.g., MAC-like clauses) were implicated. Management answered no single discrete client, described ongoing subscription migration, noted general transactional headwinds, and confirmed deal process is customary with approvals expected before year-end.

Sentiment: MIXED

Note: This summary was synthesized by AI from the CLVT Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CLVT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CLVT)

© 2026 Stock Market Info — Clarivate Plc (CLVT) Financial Profile